RaySearch Laboratories AB Stock

Equities

RAY B

SE0000135485

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Stockholm 11:29:49 2024-04-19 am EDT 5-day change 1st Jan Change
114 SEK -1.72% Intraday chart for RaySearch Laboratories AB -5.00% +26.25%
Sales 2023 1.02B 93.11M Sales 2024 * 1.14B 103M Capitalization 3.98B 362M
Net income 2023 81M 7.38M Net income 2024 * 127M 11.57M EV / Sales 2023 3.21 x
Net Debt 2023 186M 16.92M Net Debt 2024 * 82.48M 7.51M EV / Sales 2024 * 3.58 x
P/E ratio 2023
37.9 x
P/E ratio 2024 *
31.4 x
Employees 388
Yield 2023
0.78%
Yield 2024 *
1.29%
Free-Float 71.84%
More Fundamentals * Assessed data
Dynamic Chart
National Institutes for Quantum Science and Technology Selects RaySearch Laboratories AB for Clinical Use at the QST Hospital CI
Transcript : RaySearch Laboratories AB, 2023 Earnings Call, Feb 23, 2024
RaySearch Laboratories AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
RaySearch Laboratories AB Proposes an Extra Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024 CI
RaySearch Laboratories AB Proposes Ordinary Dividend for the Year Ended December 31, 2023, Payable on May 29, 2024 CI
Pharmacolog Sells Druglog Product Line to RaySearch Laboratories MT
RaySearch Laboratories AB (OM:RAY B) acquired product line Druglog of Pharmacolog AB for SEK 8.5 million. CI
The Royal Marsden Nhs Foundation Trust to Implement Online Adaptiation Therapy Utilizing Artemis from Raysearch CI
The Froedtert & Medical College of Wisconsin Health Network Selects RayStation CI
RaySearch Laboratories AB Releases Raystation 2024A CI
Vejle Hospital Becomes First Center in the World to Use RayStation for an Online Adaptive Treatment with Augmented CBCT CI
Transcript : RaySearch Laboratories AB, Q3 2023 Earnings Call, Nov 17, 2023
RaySearch Laboratories AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Oregon Health & Science University to Utilize RayStation Technology for Radiation Therapy Planning CI
Baptist Health Lexington Selects RayStation CI
More news

Latest transcript on RaySearch Laboratories AB

1 week-3.67%
Current month+0.52%
1 month+8.24%
3 months+24.17%
6 months+36.16%
Current year+28.02%
More quotes
1 week
110.80
Extreme 110.8
121.40
1 month
105.60
Extreme 105.6
123.80
Current year
84.10
Extreme 84.1
123.80
1 year
55.60
Extreme 55.6
123.80
3 years
40.00
Extreme 40
123.80
5 years
40.00
Extreme 40
193.00
10 years
36.00
Extreme 36
274.50
More quotes
Managers TitleAgeSince
Founder 55 99-12-31
Director of Finance/CFO 55 23-07-06
Chief Tech/Sci/R&D Officer 51 00-12-31
Members of the board TitleAgeSince
Founder 79 99-12-31
Founder 55 99-12-31
Chairman 86 04-04-30
More insiders
Date Price Change Volume
24-04-19 114 -1.72% 32 592
24-04-18 116 -0.51% 64,460
24-04-17 116.6 +0.87% 39,451
24-04-16 115.6 -0.69% 62,033
24-04-15 116.4 -3.00% 28,825

Delayed Quote Nasdaq Stockholm, April 19, 2024 at 05:14 am EDT

More quotes
RaySearch Laboratories publ AB is a Sweden-based medical technology company that develops software for radiation therapy of cancer. It markets and sells its products mainly in the United States and in Europe through license agreements with medical technology companies and scientific institutions. As of December 31, 2011, 15 of the Company’s products were launched, including the software platform ORBIT (optimization of radiation therapy beams by iterative technique), which is available in its main products, and is a non-clinical system which functions as a research and development environment. Additionally, its solutions include software for optimizing Intensity Modulated Radiation Therapy (IMRT) plans for photons, adaptive technology for IMRT treatments and software for proton treatments. The Company’s commercial partners are Philips, Nucletron and IBA Dosimetry, among others. In April 2014, it established a German subsidiary, RaySearch Germany GmbH.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
116 SEK
Average target price
135 SEK
Spread / Average Target
+16.38%
Consensus

Annual profits - Rate of surprise